logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical confirms its first peptide with promising preclinical potential as a non-addictive painkiller

The company said the preclinical peptide demonstrated effectiveness in alleviating moderate inflammatory pain after a single dose

PreveCeutical Medical Inc. - PreveCeutical confirms its first peptide with promising preclinical potential as a non-addictive painkiller
The company’s non-addictive analgesic program has identified its first peptide with clear in-vivo activity in a rat model of inflammatory pain

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF), the health sciences company developing preventative therapies, has confirmed its first peptide with promising preclinical potential as a non-addictive painkiller.

The Vancouver-based company shared the news in a positive update on Wednesday on its non-addictive analgesic dynorphin pain peptide program.

After shortlisting of a panel of peptides showing “promising cell-based activity” and “extended stability” in two distinct types of biological media, the program has identified its first peptide with clear "in vivo activity in a rat model” of inflammatory pain, PreveCeutical said in the statement.

The pre-clinical peptide has “demonstrated effectiveness in alleviating moderate inflammatory pain” after administration of a single dose, said the company. Researchers at PreveCeutical plan to test other shortlisted peptides from the panel for their analgesic activity in the in-vivo rat model.

This outcome highlights the “potential of appropriately designed, opioid-receptor selective peptides” in alleviating pain, said the company.

"This novel peptide has the potential for further development as a non-addictive analgesic drug candidate, based on the 'pre-clinical' animal studies that have been conducted so far," said Dr Mak Jawadekar who is the CEO of PreveCeutical Medical.

The Canadian health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive 

Quick facts: PreveCeutical Medical Inc.

Price: 0.035 CAD

CSE:PREV
Market: CSE
Market Cap: $13.88 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

on 15/11/19

2 min read